ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1600

Real-world clinical effectiveness of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis: a National multicenter study

(1592–1611) Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1444

Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1453

Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1629

Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1358

Real-World Evidence for the Superiority of Subcutaneous Methotrexate in RA: A Comparative Observational Study with Ultrasonographic Assessment

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1038

Real-World Immunosuppressant Treatment Patterns in Lupus Nephritis: A Retrospective Claims Database Analysis in the United States

(1038–1054) Health Services Research Poster II

10:30AM-12:30PM: Abstract Number: 1165

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1550

Real-World Outcomes of Anifrolumab in Systemic Lupus Erythematosus Patients at Toronto Lupus Program

(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1457

Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study

(1434–1466) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1586

Real-World Safety and Efficacy of JAK Inhibitors in Systemic Sclerosis: A Propensity-Matched EUSTAR Study

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1282

Real-world use of belimumab in childhood-onset SLE in Spain: cross-sectional analysis from a multicenter study (JULES registry)

(1272–1305) Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1021

Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1430

Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis

(1405–1433) Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0931

Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage

(0916–0933) Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1015

Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network

(1007–1037) Epidemiology & Public Health Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].